Paper35360522
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.
Costentin C and 26 others. JHEP Rep, 2022. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. Papers, record 35360522. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35360522
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03775863 | AFP Model and Liver Transplantation. | Derived from the trial | Yes |
Source ClinicalTrials.gov
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10573522 | Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. | Hepatology | 1999 | https://conductscience.org/library/papers/10573522 | PubMed |
| 2 | 29376136 | Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort. | Hepatoma Res | 2018 | https://conductscience.org/library/papers/29376136 | PubMed |
| 3 | 26058462 | Clinicopathological indices to predict hepatocellular carcinoma molecular classification. | Liver Int | 2016 | https://conductscience.org/library/papers/26058462 | PubMed |
| 4 | 22282466 | The use and interpretation of competing risks regression models. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22282466 | PubMed |
| 5 | 28199760 | Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models. | Liver Int | 2017 | https://conductscience.org/library/papers/28199760 | PubMed |
| 6 | 29433850 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. | Lancet | 2018 | https://conductscience.org/library/papers/29433850 | PubMed |
| 7 | 32201284 | Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. | J Hepatol | 2020 | https://conductscience.org/library/papers/32201284 | PubMed |
| 8 | 16794527 | Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. | Transplantation | 2006 | https://conductscience.org/library/papers/16794527 | PubMed |
| 9 | 33479224 | Hepatocellular carcinoma. | Nat Rev Dis Primers | 2021 | https://conductscience.org/library/papers/33479224 | PubMed |
| 10 | 24943720 | Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. | Transpl Int | 2014 | https://conductscience.org/library/papers/24943720 | PubMed |
| 11 | 11391528 | Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. | Hepatology | 2001 | https://conductscience.org/library/papers/11391528 | PubMed |
| 12 | 31972705 | Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival. | Transplantation | 2020 | https://conductscience.org/library/papers/31972705 | PubMed |
| 13 | 16106022 | Reporting recommendations for tumor marker prognostic studies (REMARK). | J Natl Cancer Inst | 2005 | https://conductscience.org/library/papers/16106022 | PubMed |
| 14 | 23278125 | Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. | Aliment Pharmacol Ther | 2013 | https://conductscience.org/library/papers/23278125 | PubMed |
| 15 | 18581511 | Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. | Liver Transpl | 2008 | https://conductscience.org/library/papers/18581511 | PubMed |
| 16 | 22750200 | Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. | Gastroenterology | 2012 | https://conductscience.org/library/papers/22750200 | PubMed |
| 17 | 22047762 | Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/22047762 | PubMed |
| 18 | 30229978 | Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? | Hepatology | 2019 | https://conductscience.org/library/papers/30229978 | PubMed |
| 19 | 26555945 | Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. | Transplantation | 2016 | https://conductscience.org/library/papers/26555945 | PubMed |
| 20 | 18064739 | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. | Lancet | 2007 | https://conductscience.org/library/papers/18064739 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41614008 | Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular Carcinoma. | Liver Cancer | 2025 | https://conductscience.org/library/papers/41614008 | PubMed |
| 41317084 | Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria. | Cancer Med | 2025 | https://conductscience.org/library/papers/41317084 | PubMed |
| 41249833 | Dual tissue mRNA and serum protein signatures improve risk stratification in hepatocellular carcinoma. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/41249833 | PubMed |
| 41024870 | Explant-based prognostic models for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. | World J Hepatol | 2025 | https://conductscience.org/library/papers/41024870 | PubMed |
| 40656560 | Long-Term Prognostic Value of AFP and PIVKA-II in HCC After Living Donor Liver Transplantation: A Single-Center Retrospective Study. | Transpl Int | 2025 | https://conductscience.org/library/papers/40656560 | PubMed |
| 40616813 | Recurrence of Hepatocellular Carcinoma After Liver Transplantation: The Blind Spot of HCC Management. | United European Gastroenterol J | 2025 | https://conductscience.org/library/papers/40616813 | PubMed |
| 40361345 | Development and Validation of a Pre-Transplant Risk Score (LT-MVI Score) to Predict Microvascular Invasion in Hepatocellular Carcinoma Candidates for Liver Transplantation. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40361345 | PubMed |
| 40104187 | Hepatocellular carcinoma recurrence after liver transplant: An Australian single-centre study. | World J Transplant | 2025 | https://conductscience.org/library/papers/40104187 | PubMed |
| 40070978 | [Hepatocellular carcinoma (HCC)]. | Med Trop Sante Int | 2024 | https://conductscience.org/library/papers/40070978 | PubMed |
| 40067686 | A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction. | Hepatology | 2025 | https://conductscience.org/library/papers/40067686 | PubMed |
| 39749089 | Predicting Microvascular Invasion in Liver Transplant Recipients for Hepatocellular Carcinoma. | Cureus | 2024 | https://conductscience.org/library/papers/39749089 | PubMed |
| 39594819 | Response to Bridging Therapy as a Prognostic Indicator of Post-Transplantation Hepatocellular Carcinoma Recurrence and Survival: A Systematic Review. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39594819 | PubMed |
| 39503026 | Liver transplantation for hepatocellular carcinoma: a proposal for including preoperative serological indicators improves the Milan criteria expanded. | Transl Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/39503026 | PubMed |
| 39494583 | New Scenarios in Liver Transplantation for Hepatocellular Carcinoma. | Liver Int | 2025 | https://conductscience.org/library/papers/39494583 | PubMed |
| 38927509 | Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence. | Biomedicines | 2024 | https://conductscience.org/library/papers/38927509 | PubMed |
| 38619448 | Alpha-fetoprotein: Past, present, and future. | Hepatol Commun | 2024 | https://conductscience.org/library/papers/38619448 | PubMed |
| 38473400 | Impact of Pre-Liver Transplant Treatments on the Imaging Accuracy of HCC Staging and Their Influence on Outcomes. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473400 | PubMed |
| 38067299 | Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38067299 | PubMed |
| 36926237 | Current status and prospect of treatments for recurrent hepatocellular carcinoma. | World J Hepatol | 2023 | https://conductscience.org/library/papers/36926237 | PubMed |
| 35740638 | Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35740638 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35360522
GET https://conductscience.org/api/papers/v1/35360522/authors?page=2